Home > Insider Trading > Filing (0001714899-24-000206)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1714899	Denali Therapeutics Inc.	DNLI	Biological Products, (No Disgnostic Substances) (2836)	463872213

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1724310	J. Ryan Watts	C/O Denali Therapeutics Inc. 161 Oyster Point Blvd. South San Francisco CA 94080	President And Ceo	Yes	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2024-10-18	40,000	$0.68	275,807	No	4	M	Direct
Common Stock	Disposition	2024-10-18	40,000	$27.69	235,807	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (right to buy)	Disposition	2024-10-18	40,000	$0.00	40,000	$0.68

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
1,078,091		2025-08-20	No	4	M	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	2,202,604	Indirect	See footnote

Footnotes

Includes 197,200 Unvested RSUs.
The sales reported by the Reporting Person were affected pursuant to a Rule 10b5-1 trading plan adopted September 29, 2023.
The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $27.49 to $28.00 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee.
The vesting of the shares subject to the option are contingent upon the achievement of certain performance metrics. 50% of the shares subject to the option vested on March 3, 2021, and 50% of the shares subject to the option will vest on the date the closing price of Issuer's Common Stock equals or exceeds $80.00 per share on NASDAQ for 90 consecutive trading days.